The blood-brain barrier (BBB) represents both the brain's primary defense mechanism and its most significant therapeutic challenge. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), collectively known as 4R-tauopathies, BBB dysfunction plays a critical role in disease progression and treatment resistance[1][2]. This page provides comprehensive coverage of BBB biology, dysfunction mechanisms specific to tauopathies, and emerging therapeutic strategies to enhance drug delivery to the central nervous system (CNS).
The BBB is a specialized interface between the peripheral circulation and the CNS, composed of several critical elements:
Endothelial Cells: The endothelial cells lining cerebral capillaries differ from peripheral endothelium in having no fenestrations, minimal pinocytic activity, and extremely tight intercellular junctions[3].
Tight Junction Proteins: The BBB's selective permeability is primarily maintained by:
Neurovascular Unit: The BBB functions as part of a neurovascular unit comprising endothelial cells, pericytes (covering 80-90% of capillary surface), astrocyte end-feet, and neurons. This complex interaction regulates cerebral blood flow and maintains CNS homeostasis[4].
| Mechanism | Type | Example Therapeutics | Size Limit |
|---|---|---|---|
| Passive Diffusion | Paracellular | Water, small ions | <400 Da |
| Passive Diffusion | Transcellular | Lipophilic drugs | Variable |
| Carrier-Mediated | Transporters | Glucose (GLUT1), amino acids | Small molecules |
| Receptor-Mediated | Endocytosis | Transferrin, insulin | Proteins, antibodies |
| Adsorptive-Mediated | Transcytosis | Cationized proteins | Large molecules |
| Active Efflux | ATP-binding cassette | P-glycoprotein, BCRP | Various |
Efflux Transporters: P-glycoprotein (P-gp/ABCB1), breast cancer resistance protein (BCRP/ABCG2), and multidrug resistance-associated proteins (MRPs/ABCCs) actively pump xenobiotics back into the bloodstream, limiting CNS penetration of many therapeutic agents[5].
In 4R-tauopathies like CBS and PSP, BBB dysfunction arises from multiple interconnected mechanisms:
1. Endothelial Tau Pathology
2. Pericyte Degeneration
3. Astrocyte Dysfunction
4. Neurovascular Inflammation
| Biomarker | Finding in CBS/PSP | Significance |
|---|---|---|
| CSF/Serum albumin ratio | Elevated in PSP | Indicates paracellular leakage |
| CSF P-tau181 | Elevated | Reflects neuronal injury and BBB disruption |
| CSF MMP-9 | Elevated | Active tight junction degradation |
| Dynamic Contrast-Enhanced MRI | Increased Ktrans | Quantifies BBB permeability |
| Postmortem tissue | Claudin-5 reduction | Direct evidence of TJ protein loss |
Mechanism: Focused ultrasound (FUS) combined with intravenous microbubbles temporarily disrupts tight junctions through acoustic cavitation, enabling enhanced delivery of therapeutics[8][9].
Clinical Applications for CBS/PSP:
Current Trials: Several trials are investigating FUS combined with therapeutic antibodies in Alzheimer's disease, with implications for CBS/PSP[10].
Endogenous Transporters: Certain endogenous receptors are uniquely expressed at the BBB and can be exploited for drug delivery:
| Receptor | Natural Ligand | Therapeutic Application | Status |
|---|---|---|---|
| Transferrin Receptor (TfR) | Transferrin | Anti-tau antibodies | Clinical trials |
| Insulin Receptor | Insulin | Peptide delivery | Preclinical |
| LDL Receptor | Apolipoprotein E | Lipid-based delivery | Preclinical |
| LRP1 | Amyloid-beta | Antibody fragments | Phase I/II |
TfR-Targeting Approach: Antibodies engineered with enhanced affinity for the BBB transferrin receptor (TfR) demonstrate significantly improved brain penetration. This approach is being adapted for tau-targeting therapeutics[11].
Olfactory Pathway: Nasal administration can bypass the BBB through the olfactory nerve pathway directly to the CNS:
Advantages:
Therapeutics in Development:
| Agent | Mechanism | Clinical Status | Notes |
|---|---|---|---|
| Mannitol | Osmotic disruption | Approved | Requires intracarotid infusion |
| Bradykinin analog | B2 receptor activation | Clinical trials | Transient opening |
| Alkylglycerols | Membrane fluidization | Preclinical | Oral bioavailability |
| Saponins (QS-21) | Cholesterol depletion | Vaccine adjuvant | Enhances nasal delivery |
Nanoparticle Platforms Under Investigation:
| Platform | Advantages | Limitations | Stage |
|---|---|---|---|
| Liposomes | Biocompatible, tunable | Limited loading capacity | Clinical trials |
| Polymeric NPs | Controlled release | Potential toxicity | Preclinical |
| Lipid NPs (LNPs) | mRNA delivery approved | Brain targeting needed | Expanding |
| Exosomes | Endogenous, low immunogenicity | Scalability | Early clinical |
| Gold NPs | Imaging + therapy | Clearance concerns | Preclinical |
Direct CNS Administration: For proteins and large molecules that cannot cross the BBB, direct delivery to the CSF provides an alternative route:
Considerations for CBS/PSP:
| Trial ID | Intervention | Target | Phase | Status |
|---|---|---|---|---|
| NCT05855382 | FUS + Lecanemab | AD | Phase II | Recruiting |
| NCT05613517 | FUS + Gadolinium | Healthy | Phase I | Completed |
| NCT05431712 | TfR-Tau Antibody | AD | Phase I | Phase I complete |
| NCT05297202 | Lithium | PSP | Phase II | Active |
| NCT05318985 | Bepranemab | CBS/PSP | Phase II | Recruiting |
Combination Strategies:
The challenges of BBB delivery significantly impact therapeutic options for CBS/PSP:
Approved/Available Therapies with BBB Challenges:
Assessment:
Delivery Optimization:
Emerging Technologies:
Yamada K, Iwatsubo T. Tau pathology in neurodegenerative diseases: focus on 4R-tauopathies. Brain Pathology. 2023. ↩︎
Boxer AL, Langheinrich M. Progressive supranuclear palsy: clinicopathology and emerging therapeutics. Lancet Neurology. 2024. ↩︎
Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nature Reviews Neuroscience. 2006. ↩︎
Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown and Alzheimer's disease. Nature Reviews Neurology. 2018. ↩︎
Löscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Progress in Neurobiology. 2005. ↩︎
Ghadiri M, et al. Tau pathology in the cerebral microvasculature in PSP. Acta Neuropathologica. 2020. ↩︎
Senatorov VV, et al. Reduced pericyte coverage and dysfunction in PSP. Acta Neuropathologica Communications. 2019. ↩︎
Hynynen K, et al. Focused ultrasound-induced blood-brain barrier opening: a review of hardware and clinical applications. Nature Reviews Neurology. 2023. ↩︎
Rezai AR, et al. Non-invasive opening of BBB by focused ultrasound in Alzheimer's disease. Scientific Reports. 2020. ↩︎
Lipsman N, et al. Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound. Nature Communications. 2018. ↩︎
Kariolis MS, et al. Brain delivery of therapeutic proteins by receptor-mediated transcytosis. Science Translational Medicine. 2020. ↩︎